Takeda Grabs 'Noro' Contender
LigoCyte Buyout Beats Odds; Viral 'Load' on the Front End
By Nuala Moran and Randy Osborne
Monday, October 8, 2012
It was an unlikely project, all the way around. First, getting together a syndicate of venture capital investors to bet on vaccines medicines typically given to healthy subjects, which makes possible toxicity an especially dicey proposition.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.